



## CompuGroup Medical SE & Co. KGaA

### Contact for media representatives:

Michael Franz  
Head of Brand Communication  
P +49 261 8000-6100  
E-mail: [press@cgm.com](mailto:press@cgm.com)

### Contact for analysts and investors:

Claudia Thomé  
Corporate Vice President Investor Relations  
P +49 160 3630362  
E-mail: [claudia.thome@cgm.com](mailto:claudia.thome@cgm.com)

Web: [www.cgm.com](http://www.cgm.com)

Social media: Visit us on [Facebook](#), [Twitter](#), [LinkedIn](#) and [XING](#)

*Press release, January 18, 2022*

## CompuGroup Medical expects continued strong organic growth in 2022 and first step towards higher margins

- **Cyber-attack successfully contained**
- **No significant impact on the financials, no proof for leakage of internal data**
- **All major customer systems unaffected, mandatory updates delivered in time**
- **FY 2021 prelims delayed to early March due to protective measures for internal systems**
- **2021 guidance confirmed with better-than-expected free cashflow**
- **CGM publishes guidance for 2022 in line with mid-term targets**

Koblenz. CompuGroup Medical SE & Co. KGaA (CGM), one of the leading e-health providers in the world, today reconfirms the full year guidance 2021, issues an initial full year outlook 2022 and provides an update on the cyber-attack in late December.

### **Cyber-incident update**

Following a cyber-attack on December 20, 2021, all major customer systems remain unaffected. Due to a fast reaction of all CGM teams, the Group acted quickly and decisively to protect its systems, people and customers, working with the public authorities and external

CompuGroup Medical SE & Co. KGaA · Maria Trost 21 · 56070 Koblenz · T +49 261 8000-0 · F +49 261 8000-1166 · [www.cgm.com](http://www.cgm.com)  
Chairman of the Supervisory Board: Philipp von Ilberg · Company domiciled in: Koblenz, HRB 27430, Local Court Koblenz

General Partner: CompuGroup Medical Management SE · Company domiciled in: Koblenz, HRB 27343, Local Court Koblenz  
Chairman: Frank Gotthardt

Managing Directors: Dr. Dirk Wössner (CEO), Frank Brecher, Dr. Eckart Pech, Michael Rauch, Hannes Reichl

VAT ID: DE114134699 · Commerzbank Koblenz · Bank Code: 570 400 44 · Bank Account Number: 208 002 600 · IBAN: DE60 5704 0044 0208 0026 00 · BIC: COBADEFFXXX



experts to conduct a best-practice response. The company continued to conduct business in all material respects. The mandatory regulatory updates to our products have been delivered in time before the end of the year. As of today, there is no evidence for an illegal extraction or publication of data, or any proof of data having been downloaded by the attackers. Due to protective measures CGM took immediately, the internal systems were quarantined temporarily. Therefore, the publication of the preliminary results for the financial year 2021, which was originally planned for February 3, 2022, will be delayed.

### **Confirmation of FY 2021 guidance**

With the preliminary results now expected to be published in early March CompuGroup Medical reconfirms its guidance today for the financial year 2021. The group continues to expect a revenue increase to a range of EUR 1 billion to EUR 1.04 billion and an adjusted EBITDA between EUR 210 million and EUR 230 million, corresponding to a margin in a range of 20 percent to 23 percent.

For the free cashflow, CompuGroup Medical specifies its guidance, now expecting more than EUR 90 million versus an originally expected free cashflow of more than EUR 80 million.

### **Initial guidance 2022**

Based on currently available data and the expectations of business performance for the year, CompuGroup Medical expects another year with strong organic growth, driven by the investment initiative started last year. The company anticipates group revenues of EUR 1.075 billion to EUR 1.125 billion in 2022, which corresponds to an organic growth of +3 percent to +8 percent. CGM expects an adjusted EBITDA in the range of EUR 235 million to EUR 260 million, resulting in an EBITDA margin between 21 percent and 24 percent. The full guidance will be published together with the release of the preliminary FY 2021 financials.

“I am proud of how our teams reacted to the cyber-attack. With that incident now largely behind us, we are looking back at a successful year 2021, where we took the organic growth rate to a new level and laid the foundation for further growth going forward,” said Dr. Dirk Wössner, CEO of CompuGroup Medical. “For 2022, we continue to see strong tailwind from



numerous digitization initiatives in the healthcare sector, where we will benefit from our innovative product portfolio and our leadership position in the market.”

Michael Rauch, CFO of CompuGroup Medical, added: “We are pleased to confirm the FY 2021 guidance, with a free cashflow stronger than originally guided. While we continue our investment strategy for further growth in 2022, we expect to leave the margin trough behind this year, fully on track towards the mid-term targets we have communicated.”

#### **About CompuGroup Medical SE & Co. KGaA**

CompuGroup Medical is one of the leading e-health companies in the world. With a revenue base of EUR 837 million in 2020, its software products are designed to support all medical and organizational activities in doctors’ offices, pharmacies, laboratories and hospitals. Its information services for all parties involved in the healthcare system and its web-based personal health records contribute towards safer and more efficient healthcare. CompuGroup Medical’s services are based on a unique customer base of more than 1.6 million users, including doctors, dentists, pharmacists, and other healthcare professionals in inpatient and outpatient facilities. With locations in 18 countries and products in 56 countries worldwide, CompuGroup Medical is the e-health company with one of the highest coverages among healthcare professionals. More than 8,500 highly qualified employees support customers with innovative solutions for the steadily growing demands of the healthcare system.